Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

July 16, 2025

Study Completion Date

July 16, 2025

Conditions
FOXP1 Syndrome
Interventions
OTHER

Semi-structured interviews

"3 semi-structured interviews will be administered to the legal guardians or legal representative of the patient:~* Vineland Adaptive Behavior Scales II (VABS-II): assessment of adaptive skills;~* Kiddie-SADS-Lifetime Version (K-SADS-PL): assessment of general psychopathology;~* Autism Diagnostic Interview-Revised (ADI-R): assessment of autistic symptoms. The K-SADS-PL will be administered directly to the participant provided the participant is of an equivalent age of at least 5 years 11 months for receptive language and expressive language on the VABS-II, with raw scores of 35 and 92, respectively."

OTHER

Heteroquestionnaires

7 heteroquestionnaires assessing: Hyperactivity symptoms and behavioral disorders measured by the ABC Attention deficit/hyperactivity symptoms measured by the Conners 3 scale and the SAID-P Psychotic symptoms measured by the adapted GPS-ID Sensory peculiarities measured by the Sensory Profile 2 Anxiety symptoms measured by the ADAMS Sleep disorders measured by the SDSC For children, the questionnaires: ABC, Sensory Profile 2, ADAMS, SDSC will be completed collectively by the legal guardians, and the questionnaires: Conners 3, SAID-P, adapted GPS-ID will be independently completed by each legal guardian. The same for adult patients with possible second caregiver. The questionnaires Conners 3, SAID-P and adapted GPS-ID will be completed twice, with a 28-day interval, at the time of inclusion and then after the semi-structured interviews.

Trial Locations (1)

75015

Hôpital Necker-Enfants Malades, Paris

All Listed Sponsors
collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06211673 - Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome | Biotech Hunter | Biotech Hunter